CDMO: Contract Development & Manufacturing

Imagine a global fashion brand that designs every collection in house but has never operated a single stitching factory of its own, relying instead on specialist manufacturers across Asia who quietly make the actual garments under strict quality and design instructions. Big pharmaceutical companies run their manufacturing on a strikingly similar model, and the specialist factories in this analogy are what the industry calls a CDMO, a Contract Development and Manufacturing Organisation.

A CDMO does not own the drug, does not sell it under its own brand, and usually never even meets the patient who eventually takes it. What it does is take a molecule, a manufacturing process, and sometimes just an idea for a molecule, from a global pharmaceutical company and either develop the manufacturing process, produce the drug at commercial scale, or both, entirely under contract. The global pharma company retains the intellectual property, the brand and the regulatory approval, while the CDMO earns a fee or a long term supply contract for reliably making the product to exacting quality standards.

This differs from a pure generic drug maker, which develops its own version of an off patent molecule and sells it under its own brand and its own regulatory filing, taking on market risk directly. A CDMO takes on almost no market risk. Its revenue depends on manufacturing reliability, quality consistency and regulatory compliance, not on whether the underlying drug sells well in a pharmacy, which is part of why the business tends to carry a more predictable, contract backed revenue profile once relationships are established.

India built a strong CDMO industry initially under a related but distinct label, CRAMS, Contract Research and Manufacturing Services, which leaned more heavily on the research and clinical trial side alongside manufacturing. Over time, as India's own USFDA approved manufacturing capacity expanded and matured, pure CDMO work, manufacturing at scale to global regulatory standards, grew into the larger and more durable part of the business. Companies like Divi's Laboratories, Syngene International, Piramal Pharma Solutions and Suven Pharma have built substantial businesses specifically around this model, manufacturing active ingredients and finished formulations for global pharmaceutical clients rather than selling branded drugs of their own.

The China Plus One shift, where global companies deliberately diversify manufacturing away from near total dependence on China, has been a genuine tailwind for Indian CDMOs, since India offers a combination of chemistry talent, USFDA inspected plants and English language regulatory documentation that is hard to replicate quickly elsewhere. It is why so many Indian pharma companies now speak of themselves as manufacturing partners to global pharma, a description that is really just a plainer way of saying CDMO.